Join us for an expert-led AD/PD™ Research Spotlight exploring the rapidly evolving role of blood-based biomarkers in the early detection of Alzheimer’s disease.
As limitations of CSF and PET diagnostics continue to challenge scalability and access, advances in blood-based immunoassays and automated platforms are opening new pathways toward precision, reproducibility, and routine clinical implementation.
Date: 11 February 2026 
Time: 16:00 CET
Learning Objectives
By the end of this webinar, participants will be able to:
- Describe the clinical need for reliable and scalable tools to support early detection of Alzheimer’s disease.
- Explain the emerging role of blood-based biomarkers and the analytical standards required for robust assay performance.
- Identify key factors that enhance assay precision, reproducibility, and suitability for routine clinical workflows.
Speaker
Prof. Charlotte Teunissen, PhD
Professor in Neurochemistry, Amsterdam UMC
Charlotte Teunissenaims to improve care of patients with neurological diseases by developing body fluid biomarkers for diagnosis, stratification, prognosis and monitoring treatment responses. Studies of her research group span the entire spectrum of biomarker development, starting with biomarker identification, followed by assay development and validation, and extensive clinical validation to ultimately implement novel biomarkers in clinical practice. She is responsible for the Alzheimer Center Amsterdam biobank and leads several international biomarker networks, such as the CSF Society and the Alzheimer Association-Global Biomarker Standardization consortium, and the Coral proteomics consortium.
Moderator
Roman Boeer
Business Development Lead at Sysmex Europe SE
Roman Boeer is Business Development Lead at Sysmex Europe SE, where he oversees immunochemistry solutions and related laboratory automation across the EMEA region. With a strong focus on diagnostics for the early detection of neurodegenerative disorders, their work bridges innovation, clinical value, and strategic market development. With nearly 20 years of experience in the in vitro diagnostics (IVD) industry, Roman Boeer has held senior marketing and sales roles at Tecan Group, Thermo Fisher Scientific, and Sysmex, bringing deep expertise in translating advanced technologies into clinical practice.